Sculier Jp

3.7k total citations · 1 hit paper
60 papers, 2.7k citations indexed

About

Sculier Jp is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Sculier Jp has authored 60 papers receiving a total of 2.7k indexed citations (citations by other indexed papers that have themselves been cited), including 33 papers in Pulmonary and Respiratory Medicine, 25 papers in Oncology and 9 papers in Molecular Biology. Recurrent topics in Sculier Jp's work include Lung Cancer Treatments and Mutations (20 papers), Lung Cancer Diagnosis and Treatment (18 papers) and Lung Cancer Research Studies (15 papers). Sculier Jp is often cited by papers focused on Lung Cancer Treatments and Mutations (20 papers), Lung Cancer Diagnosis and Treatment (18 papers) and Lung Cancer Research Studies (15 papers). Sculier Jp collaborates with scholars based in Belgium, France and Luxembourg. Sculier Jp's co-authors include A-P Meert, J.J. Lafitte, Thierry Berghmans, Céline Mascaux, Bradley C. Martin, J‐M Verdebout, Philippe Lothaire, P. Delmotte, Marianne Paesmans and M. Dusart and has published in prestigious journals such as Journal of Clinical Oncology, British Journal of Cancer and Annals of Oncology.

In The Last Decade

Sculier Jp

58 papers receiving 2.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

ERS/ESTS clinical guidelines on fitness for radical therapy in lung cancer patients (surgery and chemo-radiotherapy)

2009 607 citations Sculier Jp et al. European Respiratory Journal profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Sculier Jp Belgium	21	1.6k	1.1k	819	401	271	60	2.7k
Hiroji Uemura Japan	27	1.2k 0.8×	696 0.6×	616 0.8×	383 1.0×	276 1.0×	232	2.7k
Dorothy Watson United States	17	2.3k 1.4×	1.8k 1.5×	374 0.5×	207 0.5×	298 1.1×	31	3.1k
Tetsu Shinkai Japan	29	1.8k 1.1×	2.0k 1.8×	782 1.0×	184 0.5×	196 0.7×	146	3.2k
Frederick R. Ahmann United States	27	2.6k 1.6×	804 0.7×	668 0.8×	402 1.0×	218 0.8×	65	3.9k
Guillermo López-Vivanco Spain	21	1.0k 0.6×	1.3k 1.1×	677 0.8×	405 1.0×	139 0.5×	116	2.1k
Alan P. Lyss United States	27	879 0.5×	1.2k 1.1×	374 0.5×	327 0.8×	262 1.0×	66	2.7k
Nan Bi China	28	1.4k 0.9×	901 0.8×	904 1.1×	564 1.4×	633 2.3×	211	3.0k
Adolfo Favaretto Italy	31	2.2k 1.3×	1.7k 1.5×	780 1.0×	357 0.9×	231 0.9×	136	3.7k
Paolo Carlini Italy	34	1.0k 0.6×	1.7k 1.5×	630 0.8×	774 1.9×	202 0.7×	125	3.2k
Alicia K. Morgans United States	29	1.9k 1.1×	1.1k 0.9×	557 0.7×	429 1.1×	422 1.6×	202	3.4k

Countries citing papers authored by Sculier Jp

Since Specialization

Citations

This map shows the geographic impact of Sculier Jp's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sculier Jp with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sculier Jp more than expected).

Fields of papers citing papers by Sculier Jp

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sculier Jp. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sculier Jp. The network helps show where Sculier Jp may publish in the future.

Co-authorship network of co-authors of Sculier Jp

This figure shows the co-authorship network connecting the top 25 collaborators of Sculier Jp. A scholar is included among the top collaborators of Sculier Jp based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sculier Jp. Sculier Jp is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Berghmans, Thierry, Bogdan Grigoriu, Sculier Jp, & Anne‐Pascale Meert. (2018). Les inhibiteurs des freins immunitaires (anticorps anti-PD1 et anti-PD-L1), une nouvelle arme thérapeutique dans les cancers bronchiques non à petites cellules. Revue des Maladies Respiratoires. 35(2). 197–205. 4 indexed citations

Camus, M., Lieveke Ameye, Thierry Berghmans, et al.. (2014). Rate and patterns of ICU admission among colorectal cancer patients: a single-center experience. Supportive Care in Cancer. 23(6). 1779–1785. 11 indexed citations

Berghmans, Thierry, Lieveke Ameye, Luc Willems, et al.. (2013). Identification of microRNA-based signatures for response and survival for non-small cell lung cancer treated with cisplatin-vinorelbine A ELCWP prospective study. Lung Cancer. 82(2). 340–345. 51 indexed citations

Jungels, Christiane, T. Berghmans, A.-P. Meert, et al.. (2011). Traitement de rattrapage par pémétrexed pour les CBNPC : étude rétrospective d’implémentation. Revue des Maladies Respiratoires. 29(1). 21–27. 4 indexed citations

Jp, Sculier & Denis Moro‐Sibilot. (2009). First- and second-line therapy for advanced nonsmall cell lung cancer. European Respiratory Journal. 33(4). 915–930. 51 indexed citations

Jp, Sculier, T. Berghmans, Frédéric Lemaître, & Frédéric Vallot. (2008). La ventilation artificielle chez les patients atteints de cancer. Revue des Maladies Respiratoires. 18(2). 137–154.

Martin, Bradley C., et al.. (2006). EGFR, c-erbB-2 and ki-67 in NSCLC and preneoplastic bronchial lesions.. PubMed. 26(1A). 135–8. 6 indexed citations

Meert, A-P, et al.. (2006). Non-invasive Ventilation in Cancer Patients: a historically matched controlled study. 1(2). 93–98. 1 indexed citations

Berghmans, T., A-P Meert, Vincent Ninane, & Sculier Jp. (2005). Mitomycin, ifosfamide, cisplatin for non-small cell lung cancer: an implementation study. Monaldi Archives for Chest Disease. 63(4). 184–92. 1 indexed citations

10.

Feoli, Francesco, Bradley C. Martin, J‐M Verdebout, et al.. (2004). Ki67 expression in bronchial preneoplastic lesions and carcinoma in situ defined according to the new 1999 WHO/IASLC criteria: a preliminary study. Histopathology. 44(1). 47–53. 17 indexed citations

11.

Meert, A-P, J‐M Verdebout, Bradley C. Martin, et al.. (2003). Epidermal growth factor receptor expression in pre-invasive and early invasive bronchial lesions. European Respiratory Journal. 21(4). 611–615. 25 indexed citations

12.

Martin, Bénédicte, M Paesmans, C. Mascaux, et al.. (2003). The role of HER-2/neu expression on the survival of patients with lung cancer: a systematic review of the literature. British Journal of Cancer. 89(6). 959–965. 86 indexed citations

13.

Meert, A-P, M Paesmans, Benjamín Martín, et al.. (2002). The role of microvessel density on the survival of patients with lung cancer: a systematic review of the literature with meta-analysis. British Journal of Cancer. 87(7). 694–701. 193 indexed citations

14.

Berghmans, T., M Paesmans, J.J. Lafitte, et al.. (2002). Therapeutic use of granulocyte and granulocyte-macrophage colony-stimulating factors in febrile neutropenic cancer patients. Supportive Care in Cancer. 10(3). 181–188. 58 indexed citations

15.

Jp, Sculier, J.J. Lafitte, M Paesmans, et al.. (2000). Phase III randomized trial comparing moderate-dose cisplatin to combined cisplatin and carboplatin in addition to mitomycin and ifosfamide in patients with stage IV non-small-cell lung cancer. British Journal of Cancer. 83(9). 1128–1135. 18 indexed citations

16.

Vermylen, P., Candice Roufosse, Arsène Burny, et al.. (1999). Carbonic anhydrase IX antigen differentiates between preneoplastic malignant lesions in non-small cell lung carcinoma. European Respiratory Journal. 14(4). 806–806. 82 indexed citations

17.

Jp, Sculier, Marianne Paesmans, J Thiriaux, et al.. (1998). Phase III randomized trial comparing cisplatin and carboplatin with or without ifosfamide in patients with advanced non-small-cell lung cancer. European Lung Cancer Working Party.. Journal of Clinical Oncology. 16(4). 1388–1396. 24 indexed citations

18.

Stahel, R., H. Lacroix, Sculier Jp, et al.. (1992). Phase I/II study of monoclonal antibody against Lewis Y hapten in relapsed small-cell lung cancer. Annals of Oncology. 3(4). 319–320. 18 indexed citations

19.

Jp, Sculier, et al.. (1988). Role of intensive care unit in a medical oncology department. European Journal of Cancer and Clinical Oncology. 24(3). 513–517. 8 indexed citations

20.

Jp, Sculier, et al.. (1988). Multiple organ failure during interleukin-2 administration and LAK cells infusion. Intensive Care Medicine. 14(6). 666–7. 20 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact